^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    GNA13 mutation

    i
    Other names: GNA13, G Protein Subunit Alpha 13, Guanine Nucleotide Binding Protein (G Protein), Alpha 13, Guanine Nucleotide-Binding Protein Subunit Alpha-13, G Alpha-13, G-Protein Subunit Alpha-13
    Entrez ID:
    10672
    Related biomarkers:
    Others
    over1year
    High-grade B-cell lymphoma with concurrent MYC rearrangement and 11q aberrations: Clinicopathologic, cytogenetic and molecular characterization of 4 cases. (PubMed, Hum Pathol)
    Cases of HGBCL-MYC-11q display overlapping morphologic and immunophenotypic, as well as cytogenetic and molecular features between BL and LBL-11q, with a mutational landscape enriched for mutations recurrent in BL. Concurrent MYC rearrangement with 11q abnormalities is important to recognize especially since it has implications for their classification.
    Journal
    |
    TP53 (Tumor protein P53) • GNA13 (G Protein Subunit Alpha 13) • CCND3 (Cyclin D3) • DDX3X (DEAD-Box Helicase 3 X-Linked)
    |
    TP53 mutation • MYC rearrangement • GNA13 mutation
    over1year
    Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma. (PubMed, Signal Transduct Target Ther)
    Genetic subtype-guided targeted agents achieved encouraging clinical response when combined with immunochemotherapy. Collectively, LymphPlex provided high efficacy and feasibility, representing a step forward to the mechanism-based targeted therapy in DLBCL.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • ARID1A (AT-rich interaction domain 1A) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BCL6 (B-cell CLL/lymphoma 6) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • CD79B (CD79b Molecule) • B2M (Beta-2-microglobulin) • NOTCH2 (Notch 2) • CREBBP (CREB binding protein) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD70 (CD70 Molecule) • EP300 (E1A binding protein p300) • TNFAIP3 (TNF Alpha Induced Protein 3) • GNA13 (G Protein Subunit Alpha 13) • IRF8 (Interferon Regulatory Factor 8) • PIM1 (Pim-1 Proto-Oncogene) • TNFRSF14 (TNF Receptor Superfamily Member 14) • CCND3 (Cyclin D3) • IRF4 (Interferon regulatory factor 4) • SOCS1 (Suppressor Of Cytokine Signaling 1) • PRDM1 (PR/SET Domain 1) • STAT6 (Signal transducer and activator of transcription 6) • TNFRSF18 (TNF Receptor Superfamily Member 18) • BTG2 (BTG Anti-Proliferation Factor 2) • DDX3X (DEAD-Box Helicase 3 X-Linked) • TBL1XR1 (TBL1X Receptor 1) • ZFP36 (ZFP36 Ring Finger Protein)
    |
    TP53 mutation • ARID1A mutation • NOTCH1 mutation • EZH2 mutation • MYC expression • MYC rearrangement • STAT3 mutation • GNA13 mutation • PRDM1 mutation • IRF8 mutation • BCL2 fusion • BCL6 fusion
    over1year
    Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study. (PubMed, Am J Hematol)
    GNA13 mutant was significantly associated with an increased risk of death (HR: 6.6 [95%CI: 2.1-20.6]; p=0.0011) and shorter overall survival (p=0.0340). At the time of relapse or refractory disease, three genetic subgroups of DLBCL patients were delineated, which could help advance precision molecular medicine programs.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • KMT2D (Lysine Methyltransferase 2D) • CD79B (CD79b Molecule) • CREBBP (CREB binding protein) • GNA13 (G Protein Subunit Alpha 13) • PIM1 (Pim-1 Proto-Oncogene) • TNFRSF14 (TNF Receptor Superfamily Member 14) • SOCS1 (Suppressor Of Cytokine Signaling 1) • STAT6 (Signal transducer and activator of transcription 6) • TNFRSF18 (TNF Receptor Superfamily Member 18)
    |
    TP53 mutation • MYD88 mutation • KMT2D mutation • CD79B mutation • GNA13 mutation • TNFRSF14 mutation
    2years
    Identification of Genetic Subtypes in Follicular Lymphoma (ASH 2022)
    Here, we identified novel genetic subtypes that are distinguishable not just by unique sets of mutations, but also by their clinical associations and methylation profiles. The novel genetic profiles shed light on core pathways distinctly tied to each subtype. Targeted DNA sequencing of a limited gene panel represents a potentially accessible method of subtyping FL in the clinical setting, with implications for the understanding of responses to targeted therapy.
    Tumor Mutational Burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CREBBP (CREB binding protein) • EP300 (E1A binding protein p300) • TNFAIP3 (TNF Alpha Induced Protein 3) • GNA13 (G Protein Subunit Alpha 13) • TNFRSF14 (TNF Receptor Superfamily Member 14) • STAT6 (Signal transducer and activator of transcription 6) • TNFRSF18 (TNF Receptor Superfamily Member 18) • ATP6AP1 (ATPase H+ Transporting Accessory Protein 1)
    |
    TP53 mutation • TMB-L • EZH2 mutation • EP300 mutation • GNA13 mutation • TNFRSF14 mutation
    almost3years
    A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome. (PubMed, Blood Adv)
    In conclusion, we have identified a new pediatric type of PCNS-LBCL that is molecularly distinct from PCNS-LBCL occurring in adults, based on an absence of MYD88 mutation, CDKN2A/B homozygous deletion, deletion of HLA gene cluster, and paucity of CD79B and PRDM1 mutations, along with an enrichment for TP53, NFKBIE, and GNA13 mutations. Patients with pediatric type, MYD88-wildtype PCNS-LBCL often have long-term survival compared to their adult counterparts.
    Clinical • Clinical data • Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79B (CD79b Molecule) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • GNA13 (G Protein Subunit Alpha 13) • PRDM1 (PR/SET Domain 1) • NFKBIE (NFKB Inhibitor Epsilon)
    |
    TP53 mutation • CDKN2A deletion • MYD88 mutation • CDKN2A mutation • CD79B mutation • GNA13 mutation • PRDM1 mutation • MYD88 wild-type
    almost4years
    GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner. (PubMed, Cell Death Dis)
    Furthermore, we demonstrate that inactivating GNA13 by targeting its palmitoylation enhanced the sensitivity of GCB-DLBCL to the BCL2 inhibitor. These studies indicate that the loss-of-function mutation of GNA13 is a biomarker for BCL2 inhibitor therapy of GCB-DLBCL and that GNA13 palmitoylation is a potential target for combination therapy with BCL2 inhibitors to treat GCB-DLBCL with wild-type GNA13.
    Journal • IO biomarker
    |
    GNA13 (G Protein Subunit Alpha 13)
    |
    BCL2 expression • GNA13 mutation